Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 16/20 | 0.73 |
| ▸ | PTGER3 | P43115 | 15/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 11/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7807279 | 0.91 | PTGER4 (0.67) | PTGER4PTGER2PTGER3PTGER1L3MBTL1 | |
| SCHEMBL7957324 | 0.89 | PTGER4 (0.70) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL7957321 | 0.89 | PTGER4 (0.70) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL7804997 | 0.85 | PTGER4 (0.62) | PTGER4PTGER2PTGER3PTGER1KDM4E | |
| SCHEMBL7804999 | 0.85 | PTGER4 (0.62) | PTGER4PTGER2PTGER3PTGER1KDM4E | |
| SCHEMBL7807274 | 0.83 | PTGER4 (0.64) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL7807278 | 0.83 | PTGER4 (0.64) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL1396290 | 0.78 | ALDH1A1 (0.57) | PTGER4PTGER2PTGER3PTGER1L3MBTL1 | |
| SCHEMBL8676412 | 0.77 | PTGER4 (0.47) | PTGER4PTGER2PTGER3PTGER1L3MBTL1 | |
| SCHEMBL16038777 | 0.77 | PTGER3 (0.80) | PTGER4PTGER2PTGER3PTGER1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
| US-6211197-B1 | CARBOXYLIC ACID OR TETRAZOLE DERIVATES; ANALGESICS, ANTIPYRETICS, AND ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | PTGER4 11/4885PTGER2 2/4885PTGER3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.